Indication intelligence, analysis and sector perception

Kite Pharma (KITE) lights the fire, warming shareholders +$1.98 to $52.85

June 2, 2016 11:29am

KITE and Cell Design Labs announce a research collaboration and license agreement to develop next generation, precision-controlled CAR product candidates

My pre-open prognostication was on TARGET

Under the agreement, Cell Design Labs will develop "on/off switches" for KITE's CAR T-cell pipeline.

The Bottom Line: KITE will receive exclusive worldwide rights to develop and commercialize CAR T-cell therapies containing Cell Design Labs' "on/off switches" directed to certain targets for the treatment of acute myeloid leukemia.

KITE also has the exclusive option to develop and commercialize CAR T-cell products containing "on/off switches" directed to certain targets for the treatment of B-cell malignancies.

KITE will pay Cell Design Labs an upfront payment and additional payments to support Cell Design Labs' research.

Cell Design Labs will be eligible to receive milestone payments based upon the successful achievement of pre-specified research, clinical, regulatory and commercial milestones, as well as tiered royalties on product sales.

KITE closed at $50.87 and is UP +3.88% as the market opened - BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.